Page 179 - NobleCon19revC2_Neat

Zomedica Corp.

SELECTED FINANCIAL ITEMS ZOM

(in millions of USD)
CQ4 '22 CQ1 '23 CQ2 '23 CQ3 '23 LTM
Income Statement Key Items
Total Revenue 6.16 5.48 6.02 6.35 24.01
Gross Profit 4.29 3.84 4.05 4.36 16.54
Gross Margin 70% 70% 67% 69% 69%
EBIT (5.14) (7.51) (6.74) (5.95) (25.34)
EBIT Margin -83% -137% -112% -94% -106%
Net Income to Common Shareholders (2.81) (6.39) (5.25) (0.49) (14.93)
Net Margin -46% -116% -87% -8% -62%

Balance Sheet Key Items
Total Assets 279.61 279.60 274.78 275.05 275.05
Cash & Short Term Investments 27.40 8.35 27.95 21.78 21.78
% of Assets 10% 3% 10% 8% 8%
Current Assets -Total 123.50 130.16 139.63 115.39 115.39
% of Assets 44% 47% 51% 42% 42%
Total Liabilities 12.22 16.54 15.30 14.17 14.17
% of Assets 4% 6% 6% 5% 5%
Current Liabilities - Total 7.81 8.60 7.21 6.74 6.74
% of Assets 3% 3% 3% 2% 2%
Long Term Debt NA NA NA NA NA
% of Assets NM NM NM NM NM
Total Equity 267.39 263.06 259.48 260.88 260.88
% of Assets 96% 94% 94% 95% 95%

Cash Flow Statement Key Items
Net Cash Flow - Operating Activities (2.38) (4.26) (3.68) (3.03) (13.34)
Net Cash Flow - Investing (15.35) (14.79) 23.32 (3.12) (9.95)
Net Cash Flow - Financing 0.00 NA NA NA 0.00

Source: Capital IQ

PRICE / VOLUME

Source: Channelchek/QuoteMedia

Noble Capital Markets' Nineteenth Annual Small & Microcap Investor Conference